Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug
Patent 5795895 Issued on August 18, 1998. Estimated Expiration Date: 
June 13, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
June 13, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.InventorApplicationNo. 874329 filed on 06/13/1997US Classes:514/253.04, Bicyclo ring having the additional six-membered nitrogen hetero ring as one of the cyclos514/640, Oximes (i.e., C=N-O-)514/647, Amino nitrogen and a ring bonded directly to the same ring and any other amino nitrogen in the compound is bonded directly to one of the rings514/651, Ether oxygen is part of the chain514/654, The chain consists of two or more carbons which are unsubtituted or have acyclic hydrocarbyl substituents only514/909OBESITYExaminersPrimary: Schenkman, LeonardInternational ClassesA61K 031/50A61K 031/135 A61K 031/495 AbstractThis is a new therapy and method used to treat moderate and severe exogenous obesity by combining generic phentermine with an SSRI (selective serotonin reuptake inhibitor) drug in specific doses for a brief or even a long duration, 12 months or more. The preferred drugs for the combination are fluoxetine hydrochloride(Prozac), sertraline (Zoloft), fluvoxamine maleate (Luvox) and trazodone hydrochloride (Desyrel).Other References
Field of SearchEther oxygen is part of the chainThe chain consists of two or more carbons which are unsubtituted or have acyclic hydrocarbyl substituents only Amino nitrogen and a ring bonded directly to the same ring and any other amino nitrogen in the compound is bonded directly to one of the rings Oximes (i.e., C=N-O-) OBESITY | |
